TransCode Therapeutics Inc
Company Profile
Business description
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Contact
6 Liberty Square
Suite 2382
BostonMA02109
USAT: +1 857 837-3099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
10
Stocks News & Analysis
stocks
The shunned ASX player offering attractive value
stocks
What did Morningstar subscribers buy and sell during November?
stocks
Why we’ve downgraded this ASX software player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,728.50 | 26.20 | -0.30% |
| CAC 40 | 7,303.28 | 47.86 | 0.66% |
| DAX 40 | 20,232.14 | 215.39 | 1.08% |
| Dow JONES (US) | 44,902.13 | 196.60 | 0.44% |
| FTSE 100 | 8,335.81 | 23.60 | -0.28% |
| HKSE | 19,742.46 | 3.86 | -0.02% |
| NASDAQ | 19,680.97 | 200.06 | 1.03% |
| Nikkei 225 | 39,276.39 | 27.53 | 0.07% |
| NZX 50 Index | 12,896.67 | 196.51 | -1.50% |
| S&P 500 | 6,073.82 | 23.94 | 0.40% |
| S&P/ASX 200 | 8,462.60 | 32.60 | -0.38% |
| SSE Composite Index | 3,364.65 | 14.16 | -0.42% |